Volume 3.38 | Sep 25

Hematopoiesis News 3.38 September 25, 2012
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Recurrent Somatic TET2 Mutations in Normal Elderly Individuals with Clonal Hematopoiesis
Researchers found that TET2 mutations were specific to individuals with clonal hematopoiesis without hematological malignancies and were associated with alterations in DNA methylation. [Nat Genet] Abstract

LIVE Webinar: Faster 7-Day CFU Assays for the Enumeration of Hematopoietic Progenitor Cells in CB. Register now!
PUBLICATIONS (Ranked by impact factor of the journal)


Interactions Among HCLS1, HAX1 and LEF-1 Proteins Are Essential for G-CSF-Triggered Granulopoiesis
Scientists found that hematopoietic cell-specific Lyn substrate 1 (HCLS1) is highly expressed in human myeloid cells and that stimulation with granulocyte colony-stimulating factor (G-CSF) leads to HCLS1 phosphorylation. These data demonstrated the importance of HCLS1 in myelopoiesis in vitro and in vivo. [Nat Med] Abstract

Meis1 Regulates the Metabolic Phenotype and Oxidant Defense of Hematopoietic Stem Cells
Researchers demonstrated that the effect of Meis1 KO on hematopoietic stem cells (HSCs) is entirely mediated through reactive oxygen species where treatment of the Meis1 KO mice with the scavenger N-acetylcystein restored HSC quiescence and rescued HSC function. [Blood] Abstract

Dynamic Clonal Analysis of Murine Hematopoietic Stem and Progenitor Cells Marked by Five Fluorescent Proteins Using Confocal and Multiphoton Microscopy
Scientists demonstrated a methodology for tracing the clonal history of hematopoietic stem and progenitor cells behavior in live tissues in four dimensions. [Blood] Abstract

γ-Secretase Inhibitor I Induces Apoptosis in Chronic Lymphocytic Leukemia Cells by Proteasome Inhibition, Endoplasmic Reticulum Stress Increase and Notch Down-Regulation
Researchers investigated the mechanisms whereby γ-Secretase inhibitor I increases apoptosis of primary chronic lymphocytic leukemia cells. [Int J Cancer] Abstract

Deletion of the RNA-Editing Enzyme ADAR1 Causes Regression of Established Chronic Myelogenous Leukemia in Mice
These results uncovered a novel requirement for ADAR1 (adenosine deaminase acting on RNA-1) in myeloid leukemic cells and indicate that ADAR1 may comprise a new molecular target for chronic myelogenous leukemia-directed therapeutics. [Int J Cancer] Abstract

Molecular Characterization of Murine Acute Myeloid Leukemia Induced by 56Fe Ion and 137Cs Gamma Ray Irradiation
These data highlighted the similarities in molecular characteristics of high-linear energy transfer (LET) and low-LET radiation-induced murine acute myeloid leukemia (rAML) and confirm the presence of ongoing chromosomal and microsatellite instability in murine rAML. [Mutagenesis] Abstract

Sca-1 Is an Early-Response Target of Histone Deacetylase Inhibitors and Marks Hematopoietic Cells with Enhanced Function
Researchers showed that multiple histone deacetylase inhibitors induce Sca-1 expression on hematopoietic cells. They demonstrated that re-acquired Sca-1 expression coincided with induced self-renewal capacity as measured by in vitro re-plating assays, while Sca-1 itself was not required for the biological effects of valproic acid as demonstrated using Sca-1 deficient progenitor cells. [Exp Hematol] Abstract

Bortezomib Suppresses the Growth of Leukemia Cells with Notch1 Overexpression In Vivo and In Vitro
The results demonstrated that bortezomib shows significant anti-leukemia effect in acute T lymphoblast leukemia bearing Notch1 mutations in vitro and in vivo. [Cancer Chemother Pharmacol] Abstract


A Phase I Trial of the Anti-Inhibitory KIR Monoclonal Antibody IPH2101 for Acute Myeloid Leukemia (AML) in Complete Remission
IPH2101 is an anti-killer inhibitory receptor (KIR) monoclonal antibody that can block KIR mediated inhibition of natural killer cell to enhance cytotoxicity against AML blasts. Investigators conducted a phase I study of IPH2101 in elderly patients with AML in first complete remission. [Blood] Abstract

Efficacy of Allogeneic and Autologous Hematopoietic SCT in Patients with AML After First Complete Remission
Researchers retrospectively reviewed medical records of 127 patients with AML who received allogenic hematopoietic SCT (HSCT) or autologous-HSCT after achieving CR1 at a single medical center. [Bone Marrow Transplant] Abstract

StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Media. Come learn more.


Colony Stimulating Factors and Myeloid Cell Biology in Health and Disease
Researchers discuss controversies regarding the role of colony stimulating factors (CSFs) in controlling specific myeloid cell populations and highlight how the newly identified macrophage-CSF receptor ligand, interleukin-34, is necessitating a reassessment of the field. [Trends Immunol] Abstract

The Biology and Clinical Significance of Acquired Genomic Copy Number Aberrations and Recurrent Gene Mutations in Chronic Lymphocytic Leukemia
Scientists presented a state-of-the-art overview of the pathological anatomy of the chronic lymphocytic leukemia genome, including detailed descriptions of the anatomy of acquired genomic copy number aberrations and gene mutations. [Oncogene] Abstract

Stem Cells 2012 - Mumbai, India


Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
Constellation Pharmaceuticals, Inc. announced that it has entered into a strategic partnership with The Leukemia & Lymphoma Society® to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies. [Constellation Pharmaceuticals, Inc.] Press Release

Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product Nicord® for Hematological Malignancies
Gamida Cell announced that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company’s second pipeline product. NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells. [Gamida Cell] Press Release

Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
Baxter International Inc. and Onconova Therapeutics, Inc. announced that they have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a Phase III study for the treatment of a group of rare hematologic malignancies called Myelodysplastic Syndromes and in a Phase II/III study for pancreatic cancer. [Onconova Therapeutics, Inc.] Press Release

Dr. Yutaka Niihara: Novel Therapy Helps Ease Pain and Suffering for Sickle Cell Patients
Yutaka Niihara, M.D., M.P.H. is developing a low-cost, noninvasive treatment that helps provide relief for patients suffering from the debilitating effects of sickle cell disease. Dr. Niihara and his team of investigators discovered that L-glutamine can help alleviate many of the painful symptoms associated with sickle cell when used in powder form and added to liquid. [EurekAlert!] Press Release

Selexys Pharmaceuticals Completes $23 Million Equity Financing and Signs Agreement with Global Pharmaceutical Company
Selexys Pharmaceuticals, Corp., announced that it has successfully completed a $23 million Series A equity financing, led by MPM Capital. Additionally, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase II clinical study in patients with sickle cell disease. [Selexys Pharmaceuticals, Corp.] Press Release

UT MD Anderson Cancer Center Launches Unprecedented Moon Shots Program
The University of Texas (UT) MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. [The University of Texas MD Anderson Cancer Center] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW BIT’s 3rd Annual World Congress of Molecular & Cell Biology (CMCB 2013)
June 14-16, 2013
Suzhou, China

Visit our events page to see a complete list of events in the hematopoietic community.

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Postdoctoral Position(s) – Pharmaceutical Immunology/Hematopoietic Cell Development (National Taiwan University)

Research Associate – Quality Assurance (University of California)

Postdoctoral Position – Mouse Stem Cell Biology (University of Alabama)

Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

Scientist, Postdoctoral and Research Associate Positions (University of Miami – Sylvester Comprehensive Cancer Center)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us